What makes GLP-1 and Cagrilintide fundamentally different as research compounds?
GLP-1 and Cagrilintide both appear in the metabolic-signaling research literature and are frequently studied within the same experimental panels, but they engage entirely distinct receptor systems. GLP-1 is the native incretin peptide — the endogenous single-receptor reference that defines glucagon-like peptide-1 receptor (GLP-1R) agonism in its unmodified biological form. Cagrilintide is a synthetic, long-acting analog of amylin, a structurally unrelated peptide hormone, studied as a dual agonist at the amylin receptor complex and the calcitonin receptor (CTR) — a receptor system entirely separate from GLP-1R.
That receptor divergence is the organizing axis of this comparison. Unlike comparisons between GLP-1R agonists of increasing receptor breadth, GLP-1 and Cagrilintide do not share a common receptor target at all. Their frequent co-appearance in research panels reflects a biological question distinct from receptor-overlap pharmacology: how two hormone systems that are co-secreted from pancreatic islet tissue and jointly implicated in nutrient-response signaling interact when studied together, rather than how a shared receptor is engaged with differing breadth.
What is GLP-1 and what is its receptor target?
GLP-1, glucagon-like peptide-1, is an incretin hormone produced through post-translational processing of proglucagon in intestinal L-cells and secreted in response to nutrient ingestion in studied model systems. The catalogued reference form, GLP-1(7-37), is a 31-amino-acid peptide with a molecular weight of approximately 3337.73 g/mol and a molecular formula of C₁₅₁H₂₂₆N₄₀O₄₆.
GLP-1 is a selective agonist at GLP-1R, a class B G-protein-coupled receptor expressed in pancreatic beta cells, central nervous system nuclei involved in nutrient-response signaling, gastrointestinal tissue, and peripheral organs. GLP-1R activation couples to Gs-protein signaling, driving adenylyl cyclase activity and intracellular cyclic AMP elevation, with downstream activation of protein kinase A and exchange protein pathways. The receptor is also capable of β-arrestin-mediated signaling at higher ligand concentrations, a property that has made GLP-1R a frequently studied example of biased agonism among class B GPCRs.
Native GLP-1's principal experimental limitation is its short half-life: the enzyme dipeptidyl peptidase-4 (DPP-4) rapidly cleaves the peptide at its N-terminal region, constraining native GLP-1 to acute, short-duration research protocols. Extended-duration GLP-1R research typically substitutes DPP-4-resistant analogs, such as lipidated GLP-1(S).
What is Cagrilintide and what receptor does it target?
Cagrilintide is a synthetic, fatty-acid-modified analog of human amylin, catalogued under CAS number 1415456-99-3 with a molecular weight of approximately 4409.01 g/mol and a molecular formula of C₁₉₄H₃₁₂N₅₄O₅₉S₂. It is studied as a research proxy for amylin, the 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells, engineered with a lipid conjugate that extends stability and reduces the aggregation tendency that complicates native amylin handling in research settings.
Cagrilintide's receptor target — the amylin receptor — is structurally distinct from GLP-1R at the molecular level. The amylin receptor is not encoded by a single dedicated gene; it is formed by the calcitonin receptor (CTR), itself a class B GPCR, in complex with one of three receptor activity-modifying proteins (RAMPs), producing the AMY1, AMY2, or AMY3 receptor complexes depending on which RAMP is present. Published pharmacological research describes Cagrilintide as a dual agonist, retaining activity at CTR independent of RAMP association in addition to engaging the RAMP-associated amylin receptor complexes.
This receptor architecture places Cagrilintide research within a distinct signaling framework from GLP-1R research, despite both compounds being classified within the broader pancreatic-hormone and metabolic-signaling research literature.
How do the molecular structures of GLP-1 and Cagrilintide compare?
The structural differences between GLP-1 and Cagrilintide reflect their origin as products of entirely separate proglucagon and amylin gene systems, not variations on a shared scaffold.
Property
Native GLP-1 (7-37)
Cagrilintide
Sequence length
31 amino acids
37-amino-acid amylin backbone with fatty-acid conjugate
Fatty-acid lipidation for albumin binding and stability
Primary research liability of native form
Rapid DPP-4 cleavage
Aggregation propensity, short half-life
Structural origin
Endogenous peptide
Synthetic engineered analog
Both compounds share a design logic common across metabolic-signaling research tools — a native peptide with a short functional half-life paired, in the analog case, with lipidation chemistry to extend stability — but the underlying peptide sequences, receptor targets, and signaling mechanisms are unrelated to one another at the molecular level.
What does receptor pathway divergence mean for experimental design?
Because GLP-1R and the amylin receptor complex are distinct signaling systems, experiments using GLP-1 and experiments using Cagrilintide address non-overlapping mechanistic questions even when conducted within the same broader research program. Data generated with native GLP-1 speaks to GLP-1R-specific signaling — Gs-protein coupling, cAMP elevation, and associated downstream pathways in GLP-1R-expressing tissue. Data generated with Cagrilintide speaks to amylin receptor complex and CTR signaling, which involves distinct G-protein coupling characteristics and a receptor architecture dependent on RAMP association.
Research panels examining both compounds together are typically structured to characterize how the two hormone systems interact rather than to compare receptor selectivity breadth. Because pancreatic beta cells co-secrete both insulin-associated amylin and, indirectly through paracrine and systemic signaling, interact with GLP-1R-expressing tissue in shared physiological circuits, combination research designs use matched panels of GLP-1R-selective and amylin-receptor-selective compounds to isolate the contribution of each receptor axis. This requires receptor-selective antagonists or knockdown models for each target independently, since no single control condition addresses both receptor systems simultaneously.
Assay format is also a relevant design consideration. GLP-1R signaling readouts in cell-based systems are typically built around cAMP accumulation assays, given the receptor's Gs-coupled signaling profile. Amylin receptor complex readouts require attention to which RAMP isoform is co-expressed with CTR in the model system, since AMY1, AMY2, and AMY3 complexes are pharmacologically distinct from one another and from CTR alone. A cell line expressing CTR without the relevant RAMP will not report Cagrilintide's amylin receptor complex activity accurately, even though CTR-mediated signaling from the compound's direct CTR agonism may still be detected. This receptor-complex-composition dependency has no analog in GLP-1R research, where a single gene product defines the receptor.
What research contexts is each compound suited for?
Native GLP-1 is suited for research contexts requiring:
Acute, short-duration GLP-1R activation in cell-based assays
A receptor-selective, unmodified reference standard for GLP-1R signaling
Concentration-response characterization using the endogenous ligand sequence
Studies examining DPP-4 cleavage kinetics as the experimental variable of interest
Cagrilintide is suited for research contexts requiring:
Extended-duration amylin receptor complex and CTR engagement in signaling studies
Structural biology work on the amylin receptor complex, where native amylin's aggregation behavior limits experimental tractability
Combination research panels examining GLP-1R and amylin receptor signaling under matched conditions
Pharmacokinetic modeling where lipidation-extended half-life relative to native amylin is part of the research question
The two compounds are rarely substitutes for one another in experimental design; they are complementary tools addressing different receptor systems within the broader pancreatic-hormone signaling research space.
How do these compounds relate within Metatide's incretin-pathway research catalog?
Metatide's catalog is organized around receptor systems relevant to pancreatic hormone and metabolic signaling research. Native GLP-1 anchors the GLP-1R reference position within the incretin-pathway spectrum, alongside DPP-4-resistant analogs such as GLP-1(S) and multi-receptor GLP-1R-based agonists. Cagrilintide occupies a separate position within the catalog, representing the amylin receptor and calcitonin receptor axis rather than an extension of GLP-1R pharmacology.
Research panels designed to characterize cross-talk between incretin and amylin signaling systems draw compounds from both positions in the catalog — not because the compounds share a receptor target, but because studying the two systems in parallel, under matched conditions with receptor-selective controls, is how researchers isolate the distinct contribution each hormone axis makes to signaling observed in co-culture or in vivo model systems. Metatide holds both compound classes to a minimum purity specification of 99.0% or higher by HPLC, with batch-specific mass spectrometry identity confirmation and endotoxin testing included.
Specifications, available sizes, and pricing for Cagrilintide are on its product page. The full incretin and amylin-pathway catalog is available at all compounds.
GLP-1 and Cagrilintide are research chemicals intended for laboratory and scientific research purposes only. Not for human use. They are not drugs, supplements, or food products, and are not intended to diagnose, treat, cure, or prevent any disease. Metatide does not sell products intended for human consumption. Researchers are responsible for compliance with all applicable local, state, and federal regulations governing research chemical use in their jurisdiction.
